X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3561) 3561
Book Review (248) 248
Publication (207) 207
Book Chapter (15) 15
Conference Proceeding (11) 11
Book / eBook (6) 6
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3140) 3140
animals (1551) 1551
humans (908) 908
biochemistry & molecular biology (810) 810
kinetics (807) 807
rats (729) 729
male (708) 708
pharmacology & pharmacy (644) 644
oxidation-reduction (611) 611
flavin-adenine dinucleotide - metabolism (503) 503
amine oxidase (442) 442
female (371) 371
flavin-adenine dinucleotide - pharmacology (361) 361
flavin-containing monooxygenase (341) 341
enzymes (337) 337
spectrophotometry (310) 310
mice (296) 296
flavins - pharmacology (294) 294
metabolism (289) 289
flavin mononucleotide - pharmacology (283) 283
binding sites (260) 260
hydrogen-ion concentration (259) 259
flavin mononucleotide - metabolism (234) 234
in vitro techniques (232) 232
toxicology (232) 232
flavins - metabolism (230) 230
nadp - metabolism (223) 223
flavin (217) 217
nad - metabolism (215) 215
protein binding (207) 207
molecular sequence data (205) 205
research (205) 205
proteins (200) 200
chemistry, medicinal (198) 198
substrate specificity (195) 195
analysis (193) 193
amino acid sequence (186) 186
liver - enzymology (186) 186
monoamine oxidase - metabolism (184) 184
oxidoreductases - metabolism (184) 184
enzyme inhibitors - pharmacology (182) 182
molecular weight (181) 181
electron transport (180) 180
biophysics (179) 179
oxygenases - metabolism (176) 176
brain (175) 175
structure-activity relationship (175) 175
liver (173) 173
expression (170) 170
physiological aspects (168) 168
microsomes, liver - enzymology (166) 166
monoamine oxidase (164) 164
time factors (164) 164
cytochrome p-450 enzyme system - metabolism (162) 162
pharmacology (156) 156
flavin-adenine dinucleotide (154) 154
escherichia-coli (151) 151
oxidation (148) 148
catalysis (147) 147
flavins (147) 147
inhibition (146) 146
oxidative stress (145) 145
article (143) 143
monoamine oxidase inhibitors - pharmacology (143) 143
mitochondria (142) 142
models, molecular (142) 142
neurosciences (142) 142
cell biology (140) 140
liver - metabolism (140) 140
mutation (140) 140
flavin mononucleotide (137) 137
adult (131) 131
cattle (130) 130
dose-response relationship, drug (129) 129
identification (126) 126
purification (126) 126
multidisciplinary sciences (123) 123
riboflavin - pharmacology (122) 122
light (120) 120
microbiology (119) 119
molecular structure (119) 119
biochemistry (118) 118
oxygenases - genetics (118) 118
rabbits (118) 118
protein conformation (117) 117
riboflavin - metabolism (117) 117
microsomes, liver - metabolism (114) 114
gene expression (112) 112
inhibitors (112) 112
riboflavin (111) 111
binding (109) 109
fluorescence (109) 109
temperature (109) 109
flavin-containing monooxygenases (107) 107
chemistry (106) 106
chemistry, multidisciplinary (105) 105
mixed function oxygenases - metabolism (102) 102
rats, inbred strains (102) 102
rats, sprague-dawley (102) 102
bacteria (101) 101
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3318) 3318
Russian (137) 137
German (38) 38
Japanese (37) 37
French (21) 21
Ukrainian (10) 10
Italian (5) 5
Polish (4) 4
Bulgarian (3) 3
Chinese (3) 3
Spanish (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, pp. e99320 - e99320
Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based upon evaluations of reinforcement... 
MOVEMENT-DISORDERS | ADENOSINE A(2A) | CATECHOL-O-METHYLTRANSFERASE | A(2A) RECEPTOR ANTAGONISM | FOOD-SEEKING BEHAVIOR | NUCLEUS-ACCUMBENS DOPAMINE | NEGATIVE SYMPTOMS | MULTIDISCIPLINARY SCIENCES | MAJOR DEPRESSIVE DISORDER | ALTER RESPONSE ALLOCATION | PARKINSONS-DISEASE | Choice Behavior - drug effects | Selegiline - pharmacology | Vesicular Monoamine Transport Proteins - antagonists & inhibitors | Benzophenones - pharmacology | Male | Benzazepines - pharmacology | Xanthines - pharmacology | Rats, Sprague-Dawley | Feeding Behavior - drug effects | Depression - drug therapy | Animals | Nitrophenols - pharmacology | Dopamine Antagonists - pharmacology | Tetrabenazine - pharmacology | Depression - chemically induced | Tolcapone | Cannabinoid Receptor Antagonists - pharmacology | Antidepressive Agents - pharmacology | Bupropion - pharmacology | Drug Evaluation, Preclinical | Salicylamides - pharmacology | Pyrazoles - pharmacology | Drugs | Animal models | Parkinsons disease | Schizophrenia | Antagonists | Haloperidol | Mental depression | Mental retardation | Bupropion | Motivation | Reinforcement | Behavior | Dopamine D2 receptors | Selegiline | Carbohydrates | Adenosine | Dopamine | Decision making | Rats | Fatigue | Cannabinoid CB1 receptors | Tetrabenazine | Catecholamine | Amine oxidase (flavin-containing) | Feeding | Studies | Dopamine D1 receptors | Inhibitors | Index Medicus
Journal Article
BioMed Research International, ISSN 2314-6133, 2018, Volume 2018, pp. 4810394 - 10
Journal Article
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, ISSN 0363-6135, 11/2009, Volume 297, Issue 5, pp. H1655 - H1660
Ponnoth DS, Sanjani MS, Ledent C, Roush K, Krahn T, Mustafa SJ. Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice. Am J... 
antagonists | endothelium | RAT AORTA | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | INVOLVEMENT | GUINEA-PIG | vasorelaxation | PHARMACOLOGY | mouse aorta | PERIPHERAL VASCULAR DISEASE | adenosine agonists | ARTERY | CORONARY VASODILATION | VASOCONSTRICTION | MOUSE ISOLATED AORTA | Adenosine-5'-(N-ethylcarboxamide) - pharmacology | Endothelium, Vascular - drug effects | Male | Aorta - metabolism | Xanthines - pharmacology | Dose-Response Relationship, Drug | Female | Receptor, Adenosine A2A - genetics | Flavins - pharmacology | Vasoconstrictor Agents - pharmacology | Phenethylamines - pharmacology | Vasodilator Agents - pharmacology | Acetylcholine - pharmacology | Aorta - drug effects | Gene Expression Regulation | Vasoconstriction | Adenosine - pharmacology | Pyrimidines - pharmacology | Receptor, Adenosine A1 - metabolism | Receptor, Adenosine A2B - metabolism | Mice, Knockout | Receptor, Adenosine A2A - drug effects | Triazoles - pharmacology | Animals | Endothelium, Vascular - metabolism | Adenosine - analogs & derivatives | Aminopyridines - pharmacology | Adenosine - metabolism | Mice | Vasodilation - drug effects | In Vitro Techniques | Receptor, Adenosine A2A - deficiency | Adenosine | Dilatation | Physiological aspects | Blood vessels | Vascular endothelium | Aorta | Properties | Observations | Index Medicus
Journal Article
Progress in Neuropsychopharmacology & Biological Psychiatry, ISSN 0278-5846, 10/2012, Volume 39, Issue 1, pp. 31 - 39
Monoamine oxidase (MAO) inhibitors were the first antidepressant drugs to be prescribed and are still used today with great success, especially in patients... 
Depression | Monoamine metabolism | Moclobemide | Reversible MAO-A inhibitor | GEPIRONE EXTENDED-RELEASE | TAIL SUSPENSION TEST | PSYCHIATRY | INVOLVEMENT | REVERSIBLE INHIBITOR | INDUCED HYPERLOCOMOTION | MAJOR DEPRESSION | NEUROSCIENCES | CLINICAL NEUROLOGY | ANTI-PANIC DRUGS | EXPERIMENTAL-MODEL | MONOAMINE-OXIDASE-A | PHARMACOLOGY & PHARMACY | PLUS-MAZE | Imidazolines - antagonists & inhibitors | Anisoles - pharmacology | Male | Methysergide - pharmacology | Brain - metabolism | Dose-Response Relationship, Drug | Depression - drug therapy | Depression - metabolism | Drug Interactions | Antidepressive Agents - antagonists & inhibitors | Imidazolines - therapeutic use | Behavior, Animal - drug effects | Antidepressive Agents - pharmacology | Moclobemide - pharmacology | Haloperidol - pharmacology | Disease Models, Animal | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Imidazolines - pharmacology | Piperazines - pharmacology | Antidepressive Agents - therapeutic use | Brain - drug effects | Animals | Anisoles - antagonists & inhibitors | Anisoles - therapeutic use | Mice | Pyridines - pharmacology | Biogenic Monoamines - metabolism | Kinetics | Isoenzymes - antagonists & inhibitors | Index Medicus | Drugs | Dopamine | Cortex | Haloperidol | Serotonin S1 receptors | Amine oxidase (flavin-containing) | Antidepressants | Serotonin receptors | Neostriatum | Norepinephrine | Hippocampus | Locomotor activity | Dopamine receptors
Journal Article
BioMed Research International, ISSN 2314-6133, 01/2019, Volume 2019, pp. 8361858 - 12
Monoamine oxidases (MAOs) regulate local levels of neurotransmitters such as dopamine, norepinephrine, and serotonin and thus have been targeted by drugs for... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | CIS-RESVERATROL | MEDICINE, RESEARCH & EXPERIMENTAL | WOOD CREOSOTE | OXIDATIVE STRESS | CLINICAL-TRIAL | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | TRANS-RESVERATROL | CHEMOPREVENTIVE AGENT CURCUMIN | ENZYMATIC-ACTIVITY | MAO INHIBITORS | A REACTION | Central Nervous System Diseases - pathology | Kynuramine - chemistry | Guaiacol - administration & dosage | Humans | Monoamine Oxidase - drug effects | Aging - drug effects | Guaiacol - pharmacology | Chromatography, High Pressure Liquid | Stilbenes - pharmacology | Central Nervous System Diseases - metabolism | Resveratrol - chemistry | Monoamine Oxidase - chemistry | Guaiacol - analogs & derivatives | Inhibitory Concentration 50 | Kynuramine - pharmacology | Hydroxyquinolines - pharmacology | Phenols - pharmacology | Monoamine Oxidase Inhibitors - pharmacology | Resveratrol - pharmacology | Curcumin - pharmacology | Eugenol - analogs & derivatives | Eugenol - pharmacology | Aging - pathology | Central Nervous System Diseases - diet therapy | Aging - physiology | Phenols - chemistry | Monoamine Oxidase Inhibitors - chemistry | Oxidative Stress - drug effects | Monoamine Oxidase - metabolism | Competition | Oxidative stress | Hydrogen peroxide | Selectivity | Tissues | Zingerone | Isoeugenol | Guaiacol | Metabolites | Resveratrol | Aging | Degeneration | Curcumin | Inhibition | Recombinant | Enzymes | Dopamine | Serotonin | Gastrointestinal tract | Metabolism | Phenolic compounds | Chromatography | Amine oxidase (flavin-containing) | Hydroxyquinoline | Neurotransmitters | Brain research | Diet | Gastrointestinal system | Phenols | Norepinephrine | Potassium
Journal Article
Psychopharmacology, ISSN 0033-3158, 8/2012, Volume 222, Issue 4, pp. 709 - 719
The transition to menopause is associated with an increased risk of depressed mood.This study was conducted to investigate whether diphenyl diselenide... 
Neurosciences | Biomedicine | Ovariectomy | Serotonin | Diphenyl diselenide | Depression | Selenium | Pharmacology/Toxicology | Subchronic stress | Psychiatry | MONOAMINE-OXIDASE | ANTIDEPRESSANT-LIKE | FORCED-SWIMMING TEST | TAIL SUSPENSION TEST | PSYCHIATRY | BIS SELENIDE | MAJOR DEPRESSION | NEUROSCIENCES | 5-HT3 RECEPTORS | ESTROGEN-RECEPTOR-ALPHA | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | LOCOMOTOR RHYTHMS | Mitochondria - enzymology | Pargyline - therapeutic use | Ondansetron - pharmacology | Paroxetine - therapeutic use | Hippocampus - drug effects | Organoselenium Compounds - pharmacology | Ritanserin | Dose-Response Relationship, Drug | Depression - drug therapy | Drug Interactions | Depression - complications | Female | Hippocampus - enzymology | Immobility Response, Tonic - drug effects | Cerebral Cortex - drug effects | Benzene Derivatives - pharmacology | Organoselenium Compounds - therapeutic use | Disease Models, Animal | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Cerebral Cortex - enzymology | Serotonergic Neurons - enzymology | Serotonergic Neurons - drug effects | Stress, Psychological - drug therapy | Benzene Derivatives - therapeutic use | Organoselenium Compounds - antagonists & inhibitors | Benzene Derivatives - antagonists & inhibitors | Mice, Inbred Strains | Serotonin Antagonists - pharmacology | Ovariectomy - psychology | Piperazines - pharmacology | Depression - enzymology | Antidepressive Agents - therapeutic use | Animals | Pargyline - pharmacology | Mice | Pyridines - pharmacology | Paroxetine - pharmacology | Menopause - physiology | Stress, Psychological - enzymology | Stress, Psychological - complications | Monoamine Oxidase - metabolism | Paroxetine | Postmenopausal women | Monoamine oxidase | Analysis | Menopause | Mental depression | Neuropsychology | Psychopharmacology | Rodents | Index Medicus | Selenium compounds | pargyline | Serotonin S3 receptors | Antagonists | Serotonin S2 receptors | Amine oxidase (flavin-containing) | Stress | Post-menopause | Mood | Oil | paroxetine | Antidepressants | Swimming | Locomotor activity
Journal Article
Journal Article
Journal of Neural Transmission, ISSN 0300-9564, 4/2012, Volume 119, Issue 4, pp. 405 - 414
Rasagiline and (−)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of... 
Bcl-2 | Neurology | Neuroprotection | Neurosciences | Gene induction | Medicine & Public Health | (−)Deprenyl | Rasagiline | Type A and B monoamine oxidase | Pharmacology/Toxicology | Psychiatry | (-)Deprenyl | ANTI-APOPTOTIC BCL-2 | NEURODEGENERATIVE DISORDERS | N-METHYL(R)SALSOLINOL | ENDOGENOUS DOPAMINERGIC NEUROTOXIN | (-)-DEPRENYL | NEUROSCIENCES | CLINICAL NEUROLOGY | SELEGILINE | DEPRENYL | NEUROBLASTOMA SH-SY5Y CELLS | EXPRESSION | PARKINSONS-DISEASE | Monoamine Oxidase Inhibitors - pharmacology | Humans | RNA, Small Interfering - pharmacology | Selegiline - pharmacology | Mitochondria - metabolism | Mitochondria - drug effects | Monoamine Oxidase - genetics | RNA, Messenger - metabolism | Cycloheximide - pharmacology | Dose-Response Relationship, Drug | Up-Regulation - drug effects | Proto-Oncogene Proteins c-bcl-2 - metabolism | Transfection | Analysis of Variance | Cell Line, Tumor | Oxazoles - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Protein Synthesis Inhibitors - pharmacology | RNA Interference - physiology | Dactinomycin - pharmacology | Proto-Oncogene Proteins c-bcl-2 - genetics | Neuroblastoma - pathology | Indans - pharmacology | Monoamine Oxidase - metabolism | Oxidases | Selegiline | Anopheles | Nervous system diseases | Parkinson's disease | Messenger RNA | RNA | Analysis | Genes | Universities and colleges | rasagiline | Molecular modelling | Bcl-2 protein | Neurodegenerative diseases | mRNA | siRNA | Neurotrophic factors | Amine oxidase (flavin-containing) | Index Medicus
Journal Article
Journal of Psychopharmacology, ISSN 0269-8811, 1/2013, Volume 27, Issue 1, pp. 98 - 108
Harmine is a β-carboline alkaloid and major component of ayahuasca, a traditional South American psychoactive tea with anecdotal efficacy for treatment of... 
5-HT2A receptor | voltammetry | cocaine | ayahuasca | moclobemide | nucleus accumbens | Harmine | dopamine | ketanserin | monoamine oxidase | MONOAMINE OXIDASE-A | PSYCHIATRY | CONSTITUTIVE ACTIVITY | KINASE INHIBITORS | BETA-CARBOLINE | SYNAPTIC PLASTICITY | NEUROSCIENCES | CLINICAL NEUROLOGY | COCAINE DEPENDENCE | IN-VIVO | FUNCTIONAL SELECTIVITY | RECEPTOR ACTIVATION | PHARMACOLOGY & PHARMACY | REAL-TIME | Dopamine Agonists - pharmacology | Ketanserin - pharmacology | Monoamine Oxidase Inhibitors - pharmacology | Rats, Wistar | Nucleus Accumbens - metabolism | Dopamine - pharmacology | Harmine - pharmacology | Rats | Male | Serotonin - pharmacology | Brain - drug effects | Brain - metabolism | Cocaine - pharmacology | Animals | Cocaine-Related Disorders - metabolism | Cocaine-Related Disorders - drug therapy | Moclobemide - pharmacology | Nucleus Accumbens - drug effects | Receptor, Serotonin, 5-HT2A - metabolism | Dopamine - metabolism | Nucleus accumbens | Cocaine abuse | Care and treatment | Dopamine | Ayahuasca (Drug) | Evoked potentials (Electrophysiology) | Physiological aspects | Chemical properties | Research | Health aspects | Tea | Cocaine | Drug therapy | Psychopharmacology | Alkaloids | Brain slice preparation | Data processing | Serotonin S2 receptors | Acute effects | Amine oxidase (flavin-containing) | Neurotransmission | Index Medicus
Journal Article
BMC Neuroscience, ISSN 1471-2202, 10/2017, Volume 18, Issue 1, pp. 76 - 76
Background: Alzheimer's disease (AD) is the most prevalent form of dementia and represents one of the highest unmet requirements in medicine today. There is... 
Antipsychotic drugs | Monoamine oxidase | Schrodinger | Beta-secretase cleavage enzyme | Drug repurposing | Acetylcholinesterase | Butyrylcholinesterase | N-Methyl-d-aspartate | Alzheimer's disease | Molecular docking | BETA-SECRETASE | DESIGN | PROTEIN | N-Methyl-D-aspartate | CRYSTAL-STRUCTURE | COMPLEXES | NEUROSCIENCES | PERIPHERAL ANIONIC SITE | INHIBITORS | RECEPTORS | Haloperidol - analogs & derivatives | Humans | Receptors, N-Methyl-D-Aspartate - metabolism | Glucosides - pharmacokinetics | Psychotropic Drugs - therapeutic use | Butyrophenones - pharmacology | Antipsychotic Agents - therapeutic use | Butyrylcholinesterase - metabolism | Psychotropic Drugs - pharmacology | Norisoprenoids - pharmacokinetics | Glucosides - therapeutic use | Norisoprenoids - therapeutic use | Molecular Structure | Haloperidol - pharmacology | Glucosides - pharmacology | Butyrophenones - therapeutic use | Pimozide - therapeutic use | Psychotropic Drugs - pharmacokinetics | Alzheimer Disease - drug therapy | Haloperidol - pharmacokinetics | Haloperidol - therapeutic use | Antipsychotic Agents - pharmacokinetics | Norisoprenoids - pharmacology | Pimozide - pharmacology | Amyloid Precursor Protein Secretases - metabolism | Butyrophenones - pharmacokinetics | Aspartic Acid Endopeptidases - metabolism | Alzheimer Disease - metabolism | Drug Repositioning - methods | Molecular Docking Simulation | Antipsychotic Agents - pharmacology | Acetylcholinesterase - metabolism | Monoamine Oxidase - metabolism | Pimozide - pharmacokinetics | Methyl aspartate | Analysis | Dosage and administration | Research | Drug discovery | Drug therapy | Enzymes | Oxidative stress | Neurosciences | Dopamine | Neuroleptics | Polypeptides | Neurodegenerative diseases | Octanol | Clinical trials | Amine oxidase (flavin-containing) | Molecular weight | Psychotropic drugs | Proteins | Hypotheses | Computer applications | Dementia disorders | Ligands | b-Site APP cleaving enzyme | N-Methyl-D-aspartic acid | Dementia | Apoptosis | Index Medicus
Journal Article